Apolipoprotein A-I/HDL Infusion Therapy for Plaque Stabilization-Regression: A Novel Therapeutic Approach

Author(s): P. K. Shah

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 10 , 2007

Become EABM
Become Reviewer
Call for Editor


LDL-lowering therapies, predominantly involving statins, have been shown to significantly reduce cardiovascular events in asymptomatic subjects as well as in subjects with clinically established atherosclerotic cardiovascular disease. However, despite statin therapy, significant number of cardiovascular events continue to occur indicating the need for additional targets for atherosclerosis management. A number of pre-clinical studies have suggested that several HDL based therapies have the potential to stabilize or regress atherosclerosis consistent with epidemiologic evidence of an inverse relationship between coronary heart disease and HDL cholesterol levels. One such therapeutic approach involves direct infusion of HDL or HDL like molecules for rapid remodeling and stabilization of atherosclerosis. Pre-clinical and proof of concept type preliminary clinical studies suggest the feasibility and potential efficacy of this emerging new therapeutic paradigm.

Keywords: Atherosclerosis, HDL, Reverse cholesterol transport

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [1031 - 1038]
Pages: 8
DOI: 10.2174/138161207780487520
Price: $65

Article Metrics

PDF: 4